Fundus albipunctatus: review of the literature and report of a novel  gene mutation affecting the invariant tyrosine (p.Tyr175Phe) by unknown
HUMAN GENETICS • ORIGINAL PAPER
Fundus albipunctatus: review of the literature and report
of a novel RDH5 gene mutation affecting the invariant
tyrosine (p.Tyr175Phe)
Anna Skorczyk-Werner1 & Przemysław Pawłowski2 & Marta Michalczuk2 &
Alicja Warowicka3,4 & Anna Wawrocka1 & Katarzyna Wicher1 &
Alina Bakunowicz-Łazarczyk2 & Maciej R. Krawczyński1,3
Received: 5 November 2014 /Revised: 26 February 2015 /Accepted: 5 March 2015 /Published online: 28 March 2015
# The Author(s) 2015. This article is published with open access at Springerlink.com
Abstract Fundus albipunctatus (FA) is a rare, congenital
form of night blindness with rod system impairment,
characterised by the presence of numerous small, white-
yellow retinal lesions. FA belongs to a heterogenous group
of so-called flecked retina syndromes. This disorder shows
autosomal recessive inheritance and is caused mostly by mu-
tations in the RDH5 gene. This gene encodes the enzyme that
is a part of the visual cycle, the 11-cis retinol dehydrogenase.
This study is a brief review of the literature on FA and a report
of the first molecular evidence for RDH5 gene mutation in a
Polish patient with this rare disorder. We present a novel path-
ogenic RDH5 gene mutation in a 16-year-old female patient
with symptoms of night blindness. The patient underwent
ophthalmological examinations, including colour vision test-
ing, fundus photography, automated visual field testing, full-
field electroretinography (ERG) and spectral optical coherent
tomography (SOCT). The patient showed typical FA ERG
records, the visual field was constricted and fundus examina-
tion revealed numerous characteristic, small, white-yellowish
retinal lesions. DNA sequencing of the RDH5 gene coding
sequence (exons 2–5) enabled the detection of the homozy-
gous missense substitution c.524A>T (p.Tyr175Phe) in exon
3. This is the first report of RDH5 gene mutation that affects
the invariant tyrosine, one of the most conserved amino acid
residues in short-chain alcohol dehydrogenases/reductases
(SDRs), crucial for these enzymes’ activity. The location of
this substitution, together with its predicted influence on the
protein function, indicate that the p.Tyr175Phe mutation is the
cause of FA in our patient.
Keywords Fundus albipunctatus (FA) . RDH5 gene .
Mutation . Invariant tyrosine . Short-chain dehydrogenases/
reductases (SDRs) . Retinal pigment epithelium (RPE)
Introduction
Clinical characterisation of fundus albipunctatus
Fundus albipunctatus (FA; MIM 136880) is a rare, hereditary,
in most cases stationary, retinal disease, which is characterised
by impaired night vision and numerous small, white-
yellowish retinal lesions placed throughout the retina, except
the fovea (Sergouniotis et al. 2011). FA belongs to a heterog-
enous group of genetically determined flecked retina syn-
dromes. The symptoms of these disorders include conditions
characterised by multiple retinal yellowish-white lesions of
various sizes and configuration, without vascular or optic
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nerve abnormalities. The group of flecked retina syndromes
encompasses FA, retinitis punctata albescens, fundus
flavimaculatus (Stargardt disease), familial drusen and
fleck retina of Kandori, but far more diseases correspond
to the rather vague definition of fleck retina syndromes
(De Laey 1993; Walia et al. 2009). Moreover, there is a
collection of diseases called white dots syndromes that can
also be misdiagnosed with flecked retina syndromes.
White dots syndromes are characterised by white lesions
in the retinal pigment epithelium (RPE) or choroidal
layers. The aetiology of these disorders is unknown, but
these syndromes are suspected to be inflammatory in
nature and can be associated with uveitis (Matsumoto
et al. 2007).
FA is a form of congenital stationary night blindness.
The symptoms of defective dark adaptation may not be
perceptible to the affected person. The optic nerve heads
and the retinal vessels show no signs of irregularity. The
visual field and visual acuity examinations of patients suf-
fering from FA do not detect any abnormalities unless a
dim stimulus is used. Dim stimulus causes a worsening of
visual acuity and a constriction of the visual field. The
scotopic electroretinography (ERG) responses are reduced
after a 30–40-min period of dark adaptation, but typically
normalise after prolonged dark adaptation (Yamamoto
et al. 1999; Sergouniotis et al. 2011; Wang et al. 2012).
The photopic responses are usually normal if FA is not
accompanied by macular dystrophy. Although long-term
follow-up usually shows no progression in rods dysfunc-
tion in patients with this form of night blindness, some
patients, especially the elderly, reveal progressive cone
dystrophy (Nakamura et al. 2000, 2003; Wada et al.
2001; Niwa et a l . 2005) . Ful l - f ie ld photopic
electroretinograms of these individuals are usually severely
reduced, a bull’s eye maculopathy is often identified, and
visual fields and acuity are impaired (Nakamura et al.
2000 2003). Recently, it has been estimated that cone
dysfunction can affect more than 30 % of patients with
FA (Niwa et al. 2005; Sergouniotis et al. 2011; Pras et al.
2012). Lidén and coworkers suggested that cone dystrophy
may be either the result of impaired function of the RPE
caused by a RDH5 gene mutation or a direct consequence
of a decreased supply of 11-cis retinal to the cones (Lidén
et al. 2001).
Genetic background
FA shows an autosomal recessive inheritance pattern. In one
family with this retinal disease, autosomal dominant or
pseudodominant inheritance was suggested (Kranias et al.
1981). FA is caused almost exclusively by mutations in the
11-cis retinol dehydrogenase 5 (RDH5) gene (Yamamoto et al.
1999). However, mutations in two other genes, retinaldehyde
binding protein 1 (RLBP1) and RPE-specific protein (RPE65),
are also known to be associated with FA (Naz et al. 2011;
Schatz et al. 2011). Retinaldehyde binding protein 1 is
expressed in the RPE and Müller cells of the neuroretina,
where it carries 11-cis retinol and 11-cis retinaldehyde as li-
gands (Sparkes et al. 1992). Only a few RLBP1 gene muta-
tions in patients with FA have been reported to date (Katsanis
et al. 2001; Naz et al. 2011). Katsanis end coworkers (2001)
found a p.Arg150Gln mutation in the RLBP1 gene in a con-
sanguineous Saudi Arabian kindred with a retinal dystrophy
phenotype that fulfilled the criteria of FA in younger individ-
uals and retinitis punctata albescens in older patients. Two
homozygous RLBP1 gene mutations (p.Arg156* and
p.Gly116Arg) have also been identified in two unrelated, con-
sanguineous Pakistani families suffering from FA (Naz et al.
2011). RPE-specific protein (RPE65) is the isomerase of the
visual cycle, catalysing the conversion of all-trans retinyl ester
to 11-cis retinol (Moiseyev et al. 2005). To date, mutations in
the RPE65 gene associated with FA have only been reported
in one paper. A compound heterozygote of IVS+5G>A and
c.344 T>C mutations in the RPE65 gene was found in a
patient with FA (Schatz et al. 2011).
Most cases of FA are caused by mutations in the RDH5
gene (Gonzalez-Fernandez et al. 1999). The RDH5 gene en-
codes the enzyme that is a part of the visual cycle, the 11-cis
retinol dehydrogenase (Simon et al. 1995). The retinoid
(visual) cycle is an enzyme pathway that occurs to regenerate
the visual chromophore following light exposure (Travis et al.
2007). 11-cis retinol dehydrogenase (RDH5) is predominantly
expressed in the smooth endoplasmic reticulum of the RPE of
the eye (Simon et al. 1996). RPE cells play multiple roles
essential for visual function, such as involvement in the uptake
and metabolic processing of retinoids in the visual cycle (Si-
mon et al. 1999). RDH5 has an important role in the molecular
background of vision, as it catalyses the final step in the bio-
synthesis of 11-cis retinaldehyde, the universal chromophore
of visual pigments (Simon et al. 1995). Absorption of a pho-
ton by an opsin pigment causes isomerisation of the chromo-
phore from 11-cis retinaldehyde to all-trans retinaldehyde.
After entering the RPE cell, all-trans retinol is transferred into
all-trans retinyl esters, which are isomerised by RPE65 (RPE-
specific) protein into 11-cis retinol esters (11-cis retinol).
Then, 11-cis retinol is transported through the subretinal
space, where it is oxidated by the RDH5 enzyme into 11-cis
retinal (Simon et al. 1995; Wang et al. 2012).
Retinol dehydrogenase 5 protein consists of 318 amino
acids and is a member of the short-chain dehydrogenases/
reductases (SDR) superfamily (Simon et al. 1996). This fam-
ily encompasses at least 57 varied, well-characterised
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enzymes (Jörnvall et al. 1995), which catalyse the metabolism
of steroids, fatty acids, carbohydrates, amino acids and aro-
matic compounds (Marchler-Bauer et al. 2015). Although the
amino acids sequence identity between the members of this
large protein family is only at the 15–30% level, there are two
well-conserved regions within the enzymes’ sequences: the
motif Gly-X-X-X-Gly-X-Gly, consisting of three glycines
within a cofactor binding site for NAD(H) or NADP(H), and
the amino acid motif Tyr-X-X-X-Lys, with an invariant tyro-
sine residue inside the active site. Like all the classical SDR
enzymes, the RDH5 amino acid sequence contains these two
conserved domains: the motif Gly-Cys-Asp-Ser-Gly-Phe-Gly
at the amino acid residues 35–41 and the sequence
encompassing the invariant tyrosine Tyr-Cys-Val-Ser-Lys at
the residues 175–179 (Persson et al. 1991; Jörnvall et al.
1995; Simon et al. 1999). Retinol dehydrogenase 5 protein
is highly conserved among species (Simon et al. 1996). The
amino acid conservation of part of the active site
(encompassing three conserved residues: Ser-163, Tyr-175,
Lys-179) among RDH5 of several species and three other
short-chain dehydrogenases is shown in Fig. 1. RDH5 is an
integral membrane protein (Simon et al. 1995). It is composed
of the N-terminus (18 amino acids) located within the mem-
brane, the ectodomain encompassing the active site, which is
present in the lumen of the smooth endoplasmic reticulum
(SER) (residues 19–288), the C-terminal membrane-spanning
domain (289–310 amino acids) and the C-terminal tail (311–
318 amino acids) located in the cytosol of the RPE (Simon
et al. 1999; Ajmal et al. 2012). The different localisation of the
RDH5 domains within the RPE cell suggests that biosynthesis
of 11-cis retinaldehyde is a compartmentalised process (Si-
mon et al. 1999).
The RDH5 gene is mapped on the chromosome 12q13-
q14. The transcript (ENST00000257895) spans 1,269 bp
and contains five exons, including four coding exons (2–5).
The lengths of the coding exons are as follows: exon 2–342 bp
(32 bp of the 5′ untranslated region and 310 bp translated
sequence), exon 3–259, exon 4–164 and exon 5–384 bp (the
translated part is 221 bp) (Simon et al. 1996).
Materials and methods
This study was conducted in accordance with the tenets of the
Declaration of Helsinki. A 16-year-old female patient of Pol-
ish origin with clinical signs of night blindness was examined.
The patient underwent colour vision testing, fundus photogra-
phy, automated visual field testing (Humphrey–Zeiss), full-
field ERG and spectral optical coherent tomography (SOCT).
The electrophysiological examinations included a full-field
ERG protocol with the standard scotopic 20 min dark adapta-
tion and extended protocol with prolonged 120 min of dark
adaptation. The standard photopic ERG (30 Hz white flicker
stimulation) was performed after 10 min of light adaptation.
Voluntary informed consent for genetic examination was
obtained not only from the mother of the patient (as the patient
was underaged), but also from both parents and two sisters,
who had their blood taken for segregation analysis for the
presence of the novel mutation. Genomic DNAwas extracted
from peripheral blood using the conventional salting-out pro-
cedure. The coding regions of the RDH5 gene (exons 2–5)
were amplified and sequenced to screen for disease-causing
mutations in the patient. Eight primer pairs (including three
pairs for amplifying exon 2, two for exons 3 and 5, and one
pair for exon 4) were used following a previous report (Yama-
moto et al. 1999). A fragment of exon 3 (primer pair designed
3b) was also amplified in both parents and two sisters of the
proband. The polymerase chain reaction (PCR) products were
purifiedwith the use of ExoSAP-IT (Exonuclease I and Shrimp
Alkaline Phosphatase Cleanup for PCR products, Affymetrix)
and directly sequenced using Dye Terminator chemistry (v3.1
BigDye® Terminator, Life Technologies). The sequencing
products were separated on an ABI 3130xl capillary sequencer
(Applied Biosystems). The obtained sequences were verified
by comparing them to the reference sequence of the RDH5
gene (GenBank NM_001199771.1) and screened for muta-
tions. The in silico analysis using PROVEAN (Choi et al.
2012), SIFT (Kumar et al. 2009) and PolyPhen-2 (Adzhubei
et al. 2010) software was performed to assess the possible
functional effect of the novel missense mutation.
Fig. 1 The amino acid conservation of part of the active site (residues
157–196 according to the numbering system of theRDH5 protein) among
RDH5 of several species and three other short-chain dehydrogenases. The
red frame indicates the invariant tyrosine, while the black frame indicates
two other highly conserved residues involved in the catalytic mechanism:
serine-163 and lysine-179. The abbreviation ‘DH’ in the names of three
aligned proteins’ sequences stands for ‘dehydrogenase’
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Results
Family history
The patient has three sisters. The younger sister suffers from
astigmatism, while the mother and the two older sisters had no
ophthalmologic problems. In both the proband’s father’s eyes,
presenile cataract was revealed at the age of 38 years. He
suffered from retinal detachment in the right eye later on.
The first pregnancy of the patient’s mother ended with a still-
birth (pedigree, Fig. 2).
Clinical status
Visual acuity and colour vision in the patient were normal.
The examination of the anterior segment and the pupillary
reflexes showed no abnormalities. An eye fundus examination
revealed numerous small white-yellowish retinal lesions
mainly in the upper quadrants of the retina (Fig. 3). Examina-
tion of the visual field revealed its peripheral constriction to
approximately 10–20°. A full-field electroretinogram showed
significantly reduced scotopic responses after the standard pe-
riod of 20–30 min dark adaptation (Fig. 4a). However, after a
prolonged 120 min of dark adaptation, rod responses normal-
ised (Fig. 4b). Photopic responses in all examinations were
normal. The high-definition SOCT showed no abnormalities
of the central macular thickness in either eye, but local mod-
ulations of the RPE and IS/OS (inner segment–outer segment)
junctions corresponding with retinal flecks were identified.
Genetic analysis
As the clinical findings, especially characteristic eye fundus
appearance, indicated a suspicion of FA, searching for a mu-
tation in the RDH5 gene seemed to be the most appropriate
strategy. Bidirectional sequencing of the RDH5 gene coding
region (exons 2–5) revealed a homozygous mutation
c.524A>T in exon 3. This transversion changes codon UAC
to UUC, which results in the substitution of polar tyrosine to
non-polar phenylalanine at amino acid position 175
(p.Tyr175Phe) (Fig. 5). The in silico analysis of the predicted
influence of the p.Tyr175Phe substitution on protein function
with the use of PROVEAN software (the tolerance index
score was −3.900), as well as SIFT software (tolerance index
score 0.00), revealed that this amino acid change is deleteri-
ous. The in silico analysis using PolyPhen-2 software predict-
ed the mutation to be probably damaging (score of 1). The
c.524A>T variant was not found in a control cohort annotated
in the Exome Variant Server (EVS) database (Exome Variant
Server 2015) nor in the 1000 Genomes Project database (1000
Genomes Project Consortium 2012). The segregation analysis
of the mutation in the proband’s family revealed that both
parents and one of the proband’s sisters are heterozygous car-
riers of the c.524A>T substitution (pedigree, Fig. 2).
Mutations in the RDH5 gene: review of the literature
Since 1999, when Yamamoto et al. described the mutations in
the RDH5 gene in two unrelated patients suffering from FA
(Yamamoto et al. 1999), there have been reports of missense,
in-frame and frameshift mutations (Sergouniotis et al. 2011).
To date, more than 40 mutations in the RDH5 gene have been
reported, and most of them are missense variants (Nakamura
et al. 2000; Driessen et al. 2001; Sergouniotis et al. 2011;
Ajmal et al. 2012; Wang et al. 2012; Waldron and Medefindt
2014; Stenson et al. 2014). The list of RDH5 gene mutations
identified in patients with FA together with the regions of the
protein affected by these changes is shown in Table 1. The
RDH5 gene mutations have been identified mostly in
homozygotic or compound heterozygotic forms, but a few
Fig. 2 Pedigree and genotypes at
the RDH5 gene nucleotide
position 524 of the family with
the c.524A>T mutation. The
mutation is marked with red ‘M’
letter, while the blue ‘+’ symbol
indicates a wild-type allele. The
parents and two sisters of the
proband were involved in the
exon 3 sequencing analysis
Fig. 3 Fundus examination. a The right eye of a healthy individual, b
The right eye of the patient with the c.524A>T mutation in the RDH5
gene. Numerous small, white-yellowish retinal lesions are located in the
upper segments of the retina
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variants (p.Arg19Gly, p.Arg191Gln and p.Arg278Gln) have
been found as single heterozygous mutations (Sergouniotis
et al. 2011; Pras et al. 2012). There seems to be no hot spot
in the gene, as the reportedmutations are distributed across the
Fig. 4 Comparison of scotopic
responses after 30 and 120 min of
dark adaptation: RE, right eye;
LE, left eye. a The reduction of
scotopic responses (DA 0.009
cdxs/m2) (b-wave amplitude RE:
26.68 μV, LE: 26.53 μV, normal
260±151.4 μV), standard
electroretinography (ERG)
response (3 cdxs/m2) on the
borderline after 30 min of dark
adaptation. b The normalisation
of scotopic responses after
120 min of scotopic adaptation
(b-wave amplitude RE: 259.1 μV,
LE: 378.2 μV)
Fig. 5 A chromatogram showing the c.524A>T mutation in the RDH5
gene. a The wild-type nucleotide sequence and the wild-type protein
sequence. The orange frame indicates the most conservative element
between short-chain alcohol dehydrogenases, located within the active
site of the enzyme. Invariant tyrosine is labelled blue and indicated with
the red frame. b The nucleotide sequence of the heterozygous parent. c
The sequence of the patient with c.524A>T mutation and truncated pro-
tein sequence
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Table 1 RDH5 mutations identified in patients with fundus albipunctatus (FA)
Exon/
intron
Nucleotide position Amino acid residue Region of the protein Mutants
analysisa
Reference
Exon 2 c.55A>G p.Arg19Gly Ectodomain − Sergouniotis et al. (2011)
Exon 2 c.71_74delTGCC p.Leu24Profs*36 Ectodomain − Pras et al. (2012)
Exon 2 c.95delT p.Phe32Serfs*29 Ectodomain − Schatz et al. (2010)
Exon 2 c.98 T>C p.Ile33Thr Ectodomain − Sergouniotis et al. (2011)
Exon 2 c.98 T>A p.Ile33Asn Ectodomain − Rüther et al. (2004)
Exon 2 c.103G>A p.Gly35Ser Ectodomain, the conserved
cofactor binding motif
+ Nakamura et al. (2000); Wada et al. (2001)
Exon 2 c.124C>T p.Arg42Cys Ectodomain − Niwa et al. (2005)
Exon 2 c.129delT p.Leu44Trpfs*17 Ectodomain − Driessen et al. (2001)
Exon 2 c.160C>T p.Arg54* Ectodomain − Pras et al. (2012)
Exon 2 c.175 T>A p.Cys59Ser Ectodomain − Wang et al. (2012)
Exon 2 c.214insGTGG p.Val71fs*86 Ectodomain − Driessen et al. (2001)
Exon 2 c.218C>T p.Ser73Phe Ectodomain + Yamamoto et al. (1999)
Exon 2 c.285G>A p.Trp95* Ectodomain − Wang et al. (2012)
Intron 2 c.310+1G>A – Ectodomain − Sergouniotis et al. (2011)
Exon 3 c.319G>C p.Gly107Arg Ectodomain − Nakamura et al. (2000); Sato et al. (2004);
Hotta et al. (2003)
Exon 3 c.346G>C p.Gly116Arg Ectodomain − Sergouniotis et al. (2011)
Exon 3 c.346_347insGCA p.Gly116_Ile117insSer Ectodomain − Sergouniotis et al. (2011)
Exon 3 c.382G>A p.Asp128Asn Ectodomain + Iannaccone et al. (2007); Schatz et al. (2010);
Pras et al. (2012)
Exon 3 c.394 G>A p.Val132Met Ectodomain − Nakamura et al. (2000)
Exon 3 c.416G>T p.Gly139Val Ectodomain − Sergouniotis et al. (2011)
Exon 3 c.469C>T p.Arg157Trp Ectodomain + Cideciyan et al. (2000)
Exon 3 c.470G>A p.Arg157Gln Ectodomain − Hajali et al. (2009); Sergouniotis et al. (2011)
Exon 3 c.490G>T p.Val164Phe Ectodomain − Yamamoto et al. (2003)
Exon 3 c.500G>A p.Arg167His Ectodomain − Sekiya et al. (2003)
Exon 3 c.524A>T p.Tyr175Phe Ectodomain, the conserved
motif within the active site,
invariant tyrosine
− This study
Exon 3 c.530 T>G p.Val177Gly Ectodomain, the conserved
motif within active site
− Kuroiwa et al. (2000)
Exon 4 c.572G>A p.Arg191Gln Ectodomain − Pras et al. (2012)
Exon 4 c.625C>T p.Arg209* Ectodomain − Schatz et al. (2010)
Exon 4 c.689_690delCTinsGG p.Pro230Arg Ectodomain − Wang et al. (2008)
Exon 4 c.710A>C p.Tyr237Ser Ectodomain Sergouniotis et al. (2011)
Exon 4 c.712G>T p.Gly238Trp Ectodomain + Yamamoto et al. (1999); Gonzalez-Fernandez
et al. (1999); Hajali et al. (2009); Iannaccone
et al. (2007)
Exon 4 c.718dupG p.Ala240Glyfs*19 Ectodomain − Nakamura et al. (2000)
Exon 4 c.718delG p.Ala240Profs*7 Ectodomain − Makiyama et al. (2014)
Exon 5 c.758 T>G p.Met253Arg Ectodomain − Ajmal et al. (2012)
Exon 5 c.791 T>G p.Val264Gly Ectodomain + Hirose et al. (2000)
Exon 5 c.801C>G p.Cys267Trp Ectodomain − Driessen et al. (2001)
Exon 5 c.824_825delGA p.Arg275Profs*60 Ectodomain − Sergouniotis et al. (2011)
Exon 5 c.832C>T p.Arg278* Ectodomain − Liu et al. (2015)
Exon 5 c.833G>A p.Arg278Gln Ectodomain − Pras et al. (2012)
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entire RDH5 coding sequence. The mutations identified affect
the entire protein, except the N-terminus, with most mutations
located in the longest domain: lumenal ectodomain (see
Table 1). The analyses of biochemical defects in RDH5 mu-
tants associated with FA revealed that all the mutations tested
(marked with ‘+’ in Table 1) affect the stability and expression
level of the protein and result in subcellular mislocalisation.
Moreover, loss of enzymatic activity in vitro and in vivo has
been observed for almost all the constructed mutants (except
the mutant with amino acid change p.Ala294Pro located in the
C-terminal domain) (Yamamoto et al. 1999; Cideciyan et al.
2000; Lidén et al. 2001). Even in the absence of the enzyme
activity caused by many RDH5mutations, night vision regen-
erates after prolonged dark adaptation in patients with FA.
This fact can be explained by the results of the studies on
Rdh knockout mice models (Driessen et al. 2000; Kim et al.
2005). Driessen and coworkers revealed that transgenic mice
missing the RDH5 gene display delayed dark adaptation, but
only at a very high bleach level. The studies on Rdh5 and
Rdh11 knockout mice revealed that one more enzyme,
RDH11, appeared to have an important role in regenerating
the chromophore. These results indicate that both RDH5 and
RDH11 contribute to 11-cis retinal production (Driessen et al.
2000).
High variability of the disease’s phenotype is observed
among patients with FA carrying RDH5 mutations. They
show a variable visual acuity and variation in the density of
white flecks (from minimal white dots or even normal fundus
to numerous larger coalescent spots) (Sergouniotis et al. 2011;
Ajmal et al. 2012). Despite the observed phenotypic variabil-
ity, the presence of white dots appeared to be a common fea-
ture in patients with FA. These retinal flecks are hypothesised
to be the effect of an accumulation of toxic retinyl esters in the
RPE as the result of 11-cis retinol dehydrogenase disruption
(Driessen et al. 2000). However, it is known that, with increas-
ing age in the patients with FA or after uveitis, the dots may
fade and become smaller and discrete, especially in the far
periphery of the fundus (Yamamoto et al. 2003; Imaizumi
et al. 2005; Sergouniotis et al. 2011). Patients with mutations
in the RDH5 gene can manifest a non-progressive or progres-
sive form of the disease. It has been reported that individuals
with or without cone dystrophy also presented varying de-
grees of severity of FA (Nakamura et al. 2000, 2003;
Sergouniotis et al. 2011; Ajmal et al. 2012). Moreover, differ-
ent phenotypes have been observed in patients with the
same mutation, for example, c.928delCinsGAAG
(p.Leu310GluVal), which is the most commonly identified
RDH5 genemutation (Nakamura et al. 2000, 2003; Nakamura
and Miyake 2002; Sato et al. 2004; Pras et al. 2012; Ajmal
et al. 2012).
Therefore, based on the complete review of the literature, it
is difficult to establish any valid correlation between the
RDH5 variants and the disease. There is no significant asso-
ciation between the localisation or the type of RDH5mutation
with the severity of the disease phenotype (including electro-
physiological observations or the presence/absence of cone
dystrophy) (Sato et al. 2004; Niwa et al. 2005; Sergouniotis
et al. 2011; Pras et al. 2012).
Discussion
The differential diagnosis of flecked retina/white dots syn-
dromes can be difficult using routine ophthalmological exam-
ination. In cases of FAwith progressive cone dystrophy, signs




Nucleotide position Amino acid residue Region of the protein Mutants
analysisa
Reference
Exon 5 c.839G>A p.Arg280His Ectodomain + Gonzalez-Fernandez et al. (1999); Nakamura
et al. (2000); Kuroiwa et al. (2000); Sato
et al. (2004)
Exon 5 c.841 T>C p.Tyr281His Ectodomain − Nakamura et al. (2000); Nakamura and Miyake
(2002)
Exon 5 c.880G>C p.Ala294Pro C-terminal transmembrane
domain
+ Gonzalez-Fernandez et al. (1999); Schatz et al.
(2010)
Exon 5 c.913_917delGTGCT p.Val305Hisfs*29 C-terminal transmembrane
domain
− Ajmal et al. (2012)
Exon 5 c.928delCinsGAAG p.Leu310GluVal C-terminal transmembrane
domain
+ Nakamura et al. (2000); Nakamura and Miyake
(2002); Sato et al. (2004); Wang et al. (2008);
Liu et al. (2014); Makiyama et al. (2014)
Exon 5 c.955 T>C p.*319Argext*32 C-terminal cytosolic tail − Sergouniotis et al. (2011)
a ‘+’ indicates that the mutants were constructed for this mutation and the analysis of biochemical defects was performed (Yamamoto et al. 1999;
Cideciyan et al. 2000; Lidén et al. 2001); ‘–’ indicates that the mutants analysis have not been reported
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Small white-yellow retinal lesions could indicate the diagnosis
of fundus flavimaculatus, familial dominant drusen or retinitis
punctata albescens (De Laey 1993; Walia et al. 2009). More-
over, phenotypic variability in the fundus appearance of pa-
tients with FA has been described (Sergouniotis et al. 2011;
Ajmal et al. 2012). Electrophysiological findings, together
with the appropriate genetic analysis, appear to be crucial
tools in the differential diagnosis of FA (Pras et al. 2012).
Although decreased scotopic ERG responses could appear in
many different conditions (retinitis punctata albescens, FA,
FA with progressive cone dystrophy and Stargardt disease),
their normalisation after 120 min of dark adaptation is ob-
served mostly in FA (Table 2) (Yamamoto et al. 1999; Kanski
2003). However, retinitis punctata albescens due to RLBP1
mutation (Bothnia dystrophy) may be more difficult to distin-
guish, as in the early stages, there is phenotypic overlap with
FA. Some patients with Bothnia dystrophy show a dramatic
improvement in electroretinograms after prolonged dark ad-
aptation (Burstedt et al. 2008; Gränse et al. 2001), while some
patients with FA may present a minimal change, even after
several hours of dark adaptation (Sergouniotis et al. 2011).
Optimistically, recent studies provide hope for the success-
ful treatment of patients diagnosed with FA. Studies on mouse
models of FA demonstrated a significant improvement in rod
and cone visual function after treatment with 9-cis retinal
(Maeda et al. 2006). Moreover, the latest pilot clinical testing
on a group of patients with FA revealed that treatment with 9-
cis-β-carotene as a food supplement led to a considerable
visual improvement. It is very promising, as there has been
no reported treatment resulting in a significant improvement
in the visual functions in patients with retinal dystrophy to
date and, what is more, this approach will also be helpful for
some patients with retinitis pigmentosa (Rotenstreich et al.
2010, 2013).
Genetic analysis of the RDH5 gene (exons 2–5) in our
patient revealed a novel, homozygous mutation c.524A>T
in exon 3. The change of the chemical properties of the
substituted amino acids and the mutation’s predicted influence
on the protein function indicate that the p.Tyr175Phemutation
is probably pathogenic. Moreover, tyrosine at position 175 of
the RDH5 protein is localised within the active site of the
enzyme, and was described as invariant tyrosine (Simon
et al. 1996). It is known that invariant tyrosines are found in
all short-chain alcohol dehydrogenases. The Tyr-X-X-X-Lys
sequence motif, a part of the substrate binding (active) site, is
the most conserved element in SDRs (Persson et al. 1991;
Jörnvall et al. 1995). To date, only one mutation in this highly
conserved motif of the human RDH5 enzyme (Tyr-Cys-Val-
Ser-Lys) has been identified. It was a substitution of valine to
glycine at amino acid position 177. This variant was found in a
boy with FA, who was a compound heterozygote of
p.Val177Gly and p.Arg280His (Kuroiwa et al. 2000), but also
in a boy diagnosed with familial fleck retina with night blind-
ness (a heterozygote of p.Val177Gly and p.Leu310GluVal)
(Hayashi et al. 2006).
The invariant tyrosine, together with the lysine at position
179 (of the human RDH5) within the conserved motif and
serine-163 (shown in Fig. 1), are involved in the catalytic
mechanism (as putative active site residues), but only tyrosine
located within this sequence is rigidly conserved in the SDR
superfamily (Jörnvall et al. 1995; Filling et al. 2001;
Oppermann et al. 2003). The role of the invariant tyrosine
was analysed in the most studied member of the SDR super-
family: Drosophila alcohol dehydrogenase (ADH). Albalat
and González-Duarte (1992) constructed a Drosophila alcohol
dehydrogenase, in which the invariant tyrosine (at amino acid
position 152) was substituted by phenylalanine. Drosophila
alcohol dehydrogenase-phenylalanine-152 revealed no enzy-
matic activity. Therefore, it is very likely that substitution of
the invariant tyrosine to phenylalanine in human retinol dehy-
drogenase (RDH5) protein would have a similarly damaging
effect to that reported in Drosophila ADH.
Table 2 Comparison of conditions with the symptom of small white-yellow retinal lesions



















Visual field Normal Can be constricted Constricted Can be constricted Peripherally constricted
Retinal vessels Normal Normal Attenuated Can be attenuated Normal
ERG Depressed rods
responses
Depressed rods responses Depressed rods
responses






Proper scotopic responses Depressed scotopic
response
Variable Proper scotopic responses
mfERG Normal Reduced cones density Normal Decreased central Reduced cones density in
peripheral rings
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The segregation analysis of the presence of the c.524A>T
mutation in the family studied was found to be consistent with
the autosomal recessive mode of inheritance. It revealed that
both the proband’s parents are heterozygous carriers of this
novel substitution. Therefore, it is highly probable that they
are related. We did not confirm this assumption based on the
exact pedigree data, but the parents’ families come from vil-
lages located in very close proximity.
To conclude, we have presented a brief but complete re-
view of the literature on FA, focusing on the genetic back-
ground of the disease. Our study expands the spectrum of
RDH5 mutations, as we also report the novel mutation in the
11-cis retinol dehydrogenase 5 gene. This study is the first
report of a RDH5 gene mutation that affects the invariant
tyrosine, one of the most conserved amino acid residues in
SDRs, crucial for these enzymes’ activity. The location of
the substitution, together with the mutation’s predicted influ-
ence on protein function, indicate that the p.Tyr175Phe muta-
tion is probably pathogenic and can be recognised as the cause
of FA. Moreover, we have presented the first molecular evi-
dence for 11-cis retinol dehydrogenase 5 (RDH5) gene muta-
tion in a Polish patient with this rare retinal disease. This study
may also help clinicians to improve the difficult process of FA
differential diagnosis, in which genetic analysis is an indis-
pensable element, which would enable the correct treatment of
patients.
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